IMMP News and Press, Immutep Limited From 03/14/23

2023-03-14 09:16:22 ET Immutep ( NASDAQ: IMMP ) said it started a phase 2/3 trial of eftilagimod alpha (efti) in combination with paclitaxel to treat metastatic HER2-neg/low breast cancer (MBC). The company has received regulatory approval in the U.S. and greenlight from t...

Media Release Integrated Phase II/III trial design incorporates feedback from the FDA and EMA and will help inform a BLA and MAA HR+/HER2-neg/low metastatic breast cancer (MBC) patient population has been expanded to include triple-negative breast cancer, which together account for ~7...

2023-03-07 07:49:29 ET Stocks and exchange traded funds linked to the Australian stock market gained ground during Tuesday's premarket trading in the U.S after the Reserve Bank of Australia raised interest rates by 25 basis points. The RBA moved its cash rate to 3.6%, which marked t...

Media Release 20 patients with 1st line non-small cell lung cancer (1L NSCLC) now enrolled in the first triple combination therapy study of efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy Promising initial efficacy results showing a 72.7% response rate and...

Summary Today, we revisit a small cap oncology concern called Immutep Limited for the first time in two years. The company is advancing its primary drug candidate on multiple fronts and targeting some significant potential markets. An investment analysis follows in the paragraphs be...

SYDNEY, AUSTRALIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that it has enrolle...

Immutep ( NASDAQ: IMMP ) ( OTCPK:PRRUF ) said it had a positive follow-up Type C meeting with the U.S. Food and Drug Administration (FDA) regarding late-stage clinical development plans for eftilagimod alpha (efti), with standard-of-care chemotherapy, to treat metastatic brea...

Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha’s potential to address high unmet need for metastatic breast cancer patients Patient population expanded to include patients with triple-negative breast cancer Late-stage clinical dev...

Media Release First 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein Completed by Wu X i Biologics SYDNEY, AUSTRALIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company...

Media Release SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced t...